Skip to main content
Equibles
MDGL logo

MDGL · Madrigal Pharmaceuticals, Inc. · Earnings Call Transcripts & Audio

Track MDGL — free

Use MDGL with AI

Add company filings, earnings and prices to ChatGPT or Claude, then ask questions in your own chat.

Choose your app for step-by-step connection instructions. Sign in with Equibles when asked; no code or API key is needed.

Claude ChatGPT

After connecting, ask your AI to use Equibles to research MDGL.

Other apps & server URL
https://mcp.equibles.com/mcp
Gemini CLI setup
or ask here

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

See what you can ask in ChatGPT or Claude

All connection guides →
$503.96 -5.48 (-1.08%) At close · Sep 30
Russell 1000 member Rebalance outlook locked
Market Cap
$11.93B
Shares
23.10M
Volume · Sep 30 262.51K Avg daily vol (3M) 294.77K

Madrigal Pharmaceuticals, Inc. Earnings Call Transcripts

Quarterly earnings calls for Madrigal Pharmaceuticals, Inc. (MDGL), with available speaker-labelled transcripts, captured audio replays, call highlights, 8-K earnings releases and periodic filings. Investor days and conferences appear here too.

Pull transcripts and briefs through the earnings call transcript API or MCP →

Revenue & result across quarters

Revenue Net income YoY up YoY down artefacts
· $ −$63.10M '21 Q3 21-11-04 · $ −$57.52M '22 Q1 22-05-09 · $ −$147.54M '24 Q1 24-05-07 · $14.64M −$151.97M '24 Q2 24-08-07 · $62.17M −$106.96M '24 Q3 24-10-31 · $103.32M −$59.42M '24 Q4 25-02-26 · $137.25M −$73.24M '25 Q1 25-05-01 ▲1353.8% $212.80M −$42.28M '25 Q2 25-08-05 ▲362% $287.27M −$114.19M '25 Q3 25-11-04 ▲210.8% $321.08M −$58.58M '25 Q4 26-02-19 ▲126.8% $311.34M −$94.39M '26 Q1 26-05-06 LATEST ▲71.2% $364.25M −$57.94M '26 Q2 26-07-30
Conference
Investor event
2026-08-11
Madrigal Pharmaceuticals, Inc. (MDGL) August 2026 Conference Transcript
No reported result — non-financial event
Audio Transcript Slides
Earnings call
FY26 · Q2
2026-07-30
Madrigal Pharmaceuticals, Inc. (MDGL) Q2 2026 Earnings Call Transcript
Confident tone ResDifera Commercial Performance MASH Market Expansion Intellectual Property / Patent Estate
Revenue
$364.25M
▲ 71.2% YoY
Diluted EPS
$-1.99
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Conference
Investor event
2026-06-10
Madrigal Pharmaceuticals, Inc. (MDGL) June 2026 Conference Transcript
No reported result — non-financial event
Audio Transcript Slides
Earnings call
FY26 · Q1
2026-05-06
Madrigal Pharmaceuticals, Inc. (MDGL) Q1 2026 Earnings Call Transcript
Confident tone F4C compensated cirrhosis indication expansion MASH market opportunity and expansion Path to peak sales and long-term outlook
Revenue
$311.34M
▲ 126.8% YoY
Diluted EPS
$-3.25
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Conference
Investor event
2026-03-03
Madrigal Pharmaceuticals, Inc. (MDGL) March 2026 Conference Transcript
No reported result — non-financial event
Audio Transcript Slides
Earnings call
FY25 · Q4
2026-02-19
Madrigal Pharmaceuticals, Inc. (MDGL) Q4 2025 Earnings Call Transcript
Confident tone Rezdiffra launch and net sales performance F4C (compensated NASH cirrhosis) opportunity Patent exclusivity
Revenue
$321.08M*
▲ 210.8% YoY
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-K
Earnings call
FY25 · Q3
2025-11-04
Madrigal Pharmaceuticals, Inc. (MDGL) Q3 2025 Earnings Call Transcript
Confident tone Rezdiffra launch performance Pipeline and MAESTRO-NASH Gross to net dynamics
Revenue
$287.27M
▲ 362% YoY
Diluted EPS
$-4.01
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY25 · Q2
2025-08-05
Madrigal Pharmaceuticals, Inc. (MDGL) Q2 2025 Earnings Call Transcript
Confident tone Rezdiffra launch performance F4c compensated MASH cirrhosis / OUTCOMES trial Oral GLP-1 business development (MGL-2086)
Revenue
$212.80M
▲ 1353.8% YoY
Diluted EPS
$-1.50
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY25 · Q1
2025-05-01
Madrigal Pharmaceuticals, Inc. (MDGL) Q1 2025 Earnings Call Transcript
Revenue
$137.25M
Diluted EPS
$-2.61
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY24 · Q4
2025-02-26
Madrigal Pharmaceuticals, Inc. (MDGL) Q4 2024 Earnings Call Transcript
Confident tone U.S. Rezdiffra Launch Execution Market Penetration & Growth Opportunity F4c Cirrhosis Data & Label Expansion
Revenue
$103.32M*
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-K
Earnings call
FY24 · Q3
2024-10-31
Madrigal Pharmaceuticals, Inc. (MDGL) Q3 2024 Earnings Call Transcript
Confident tone Rezdiffra US launch performance Pipeline and long-term leadership in NASH Business development and pipeline expansion
Revenue
$62.17M
Diluted EPS
$-4.92
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY24 · Q2
2024-08-07
Madrigal Pharmaceuticals, Inc. (MDGL) Q2 2024 Earnings Call Transcript
Confident tone Patient education and disease awareness Rezdiffra launch metrics Wiring the system / physician activation
Revenue
$14.64M
Diluted EPS
$-7.10
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY24 · Q1
2024-05-07
Madrigal Pharmaceuticals, Inc. (MDGL) Q1 2024 Earnings Call Transcript
Confident tone Rezdiffra U.S. launch progress Clinical pipeline expansion Patient access and reimbursement
Revenue
$
Diluted EPS
$-7.38
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY22 · Q1
2022-05-09
Madrigal Pharmaceuticals, Inc. (MDGL) Q1 2022 Earnings Call Transcript
Revenue
$
Diluted EPS
$-3.36
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY21 · Q3
2021-11-04
Madrigal Pharmaceuticals, Inc. (MDGL) Q3 2021 Earnings Call
Revenue
$
Diluted EPS
$-3.79
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Showing 1–15 of 15 earnings calls
Key facts CIK 1157601 CUSIP 558868105 13F (30d) 9 filings 9 filers Visit website Investor relations